(Q37760515)

22 August 2017

1 reference

title

Incretin-based therapies for type 2 diabetes mellitus: current status and future prospects (English)

1 reference

22 August 2017

0 references

Scott R Drab

1

1 reference

PubMed ID

20500049

22 August 2017

language of work or name

English

0 references

publication date

1 June 2010

1 reference

22 August 2017

1 reference

22 August 2017

30

1 reference

22 August 2017

6

1 reference

22 August 2017

609-624

1 reference

Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study

22 August 2017

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.30.6.609

U.K. prospective diabetes study 16. Overview of 6 years' therapy of type II diabetes: a progressive disease. U.K. Prospective Diabetes Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.30.6.609

The prevention of type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.30.6.609

Pharmacological and surgical intervention for the prevention of diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.30.6.609

Reduction in weight and cardiovascular disease risk factors in individuals with type 2 diabetes: one-year results of the look AHEAD trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.30.6.609

Effect of a multifactorial intervention on mortality in type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.30.6.609

Is glycemic control improving in U.S. adults?

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.30.6.609

Diabetes health disparities: a systematic review of health care interventions.

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.30.6.609

Medical management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.30.6.609

Use and abuse of HOMA modeling

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.30.6.609

Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.30.6.609

Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.30.6.609

Goals of treatment for type 2 diabetes: beta-cell preservation for glycemic control

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.30.6.609

Statement by an American Association of Clinical Endocrinologists/American College of Endocrinology consensus panel on type 2 diabetes mellitus: an algorithm for glycemic control

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.30.6.609

Glucagon-like peptide I stimulates insulin gene expression and increases cyclic AMP levels in a rat islet cell line

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.30.6.609

Four weeks of near-normalisation of blood glucose improves the insulin response to glucagon-like peptide-1 and glucose-dependent insulinotropic polypeptide in patients with type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.30.6.609

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.30.6.609

GLP-1: physiological effects and potential therapeutic applications

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.30.6.609

Glucagon-like peptide 1 inhibits cell apoptosis and improves glucose responsiveness of freshly isolated human islets

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.30.6.609

Glucagon-like peptide-1 prevents beta cell glucolipotoxicity

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.30.6.609

Glucagon-like peptide 1 can directly protect the heart against ischemia/reperfusion injury

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.30.6.609

Antihypertensive effect of glucagon-like peptide 1 in Dahl salt-sensitive rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.30.6.609

Glucagon-like peptide-1 relaxes rat conduit arteries via an endothelium-independent mechanism

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.30.6.609

Normalization of glucose concentrations and deceleration of gastric emptying after solid meals during intravenous glucagon-like peptide 1 in patients with type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.30.6.609

Continuous subcutaneous infusion of glucagon-like peptide 1 lowers plasma glucose and reduces appetite in type 2 diabetic patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.30.6.609

Normalization of fasting hyperglycaemia by exogenous glucagon-like peptide 1 (7-36 amide) in type 2 (non-insulin-dependent) diabetic patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.30.6.609

Effect of 6-week course of glucagon-like peptide 1 on glycaemic control, insulin sensitivity, and beta-cell function in type 2 diabetes: a parallel-group study

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.30.6.609

Incretin-based therapies: viewpoints on the way to consensus

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.30.6.609

Proglucagon-derived peptides: mechanisms of action and therapeutic potential

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.30.6.609

Glucagon-like peptide receptor agonists and dipeptidyl peptidase-4 inhibitors in the treatment of diabetes: a review of clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.30.6.609

Effects of once-weekly dosing of a long-acting release formulation of exenatide on glucose control and body weight in subjects with type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.30.6.609

Investigation of exenatide elimination and its in vivo and in vitro degradation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.30.6.609

Effect of exenatide on the steady-state pharmacokinetics of digoxin.

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.30.6.609

Effect of exenatide on the pharmacokinetics and pharmacodynamics of warfarin in healthy Asian men.

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.30.6.609

Glucagon-like peptide-1: the basis of a new class of treatment for type 2 diabetes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.30.6.609

Structure-activity and protraction relationship of long-acting glucagon-like peptide-1 derivatives: importance of fatty acid length, polarity, and bulkiness

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.30.6.609

Thymic stromal lymphopoietin and thymic stromal lymphopoietin-conditioned dendritic cells induce regulatory T-cell differentiation and protection of NOD mice against diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.30.6.609

Pharmacokinetics, pharmacodynamics, safety, and tolerability of a single-dose of NN2211, a long-acting glucagon-like peptide 1 derivative, in healthy male subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.30.6.609

The pharmacokinetics, pharmacodynamics, safety and tolerability of NN2211, a new long-acting GLP-1 derivative, in healthy men.

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.30.6.609

Pharmacokinetics and pharmacodynamic effects of the oral DPP-4 inhibitor sitagliptin in middle-aged obese subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.30.6.609

Pharmacokinetics and pharmacodynamics of sitagliptin, an inhibitor of dipeptidyl peptidase IV, in healthy subjects: results from two randomized, double-blind, placebo-controlled studies with single oral doses

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.30.6.609

The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.30.6.609

Effect of renal insufficiency on the pharmacokinetics of sitagliptin, a dipeptidyl peptidase-4 inhibitor

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.30.6.609

Sitagliptin: a novel agent for the management of type 2 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.30.6.609

Rhabdomyolysis caused by a potential sitagliptin-lovastatin interaction

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.30.6.609

Pharmacokinetic and pharmacodynamic properties of multiple oral doses of sitagliptin, a dipeptidyl peptidase-IV inhibitor: a double-blind, randomized, placebo-controlled study in healthy male volunteers

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.30.6.609

Saxagliptin: a new dipeptidyl peptidase-4 inhibitor for the treatment of type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.30.6.609

Efficacy and tolerability of exenatide monotherapy over 24 weeks in antidiabetic drug-naive patients with type 2 diabetes: a randomized, double-blind, placebo-controlled, parallel-group study

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.30.6.609

Effects of exenatide (exendin-4) on glycemic control over 30 weeks in sulfonylurea-treated patients with type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.30.6.609

Effects of exenatide (exendin-4) on glycemic control and weight over 30 weeks in metformin-treated patients with type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.30.6.609

Tolerability and efficacy of exenatide and titrated insulin glargine in adult patients with type 2 diabetes previously uncontrolled with metformin or a sulfonylurea: a multinational, randomized, open-label, two-period, crossover noninferiority trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.30.6.609

Effects of exenatide (exendin-4) on glycemic control over 30 weeks in patients with type 2 diabetes treated with metformin and a sulfonylurea

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.30.6.609

Exenatide versus insulin glargine in patients with suboptimally controlled type 2 diabetes: a randomized trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.30.6.609

A comparison of twice-daily exenatide and biphasic insulin aspart in patients with type 2 diabetes who were suboptimally controlled with sulfonylurea and metformin: a non-inferiority study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.30.6.609

One-year treatment with exenatide improves beta-cell function, compared with insulin glargine, in metformin-treated type 2 diabetic patients: a randomized, controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.30.6.609

Exenatide once weekly versus twice daily for the treatment of type 2 diabetes: a randomised, open-label, non-inferiority study

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.30.6.609

Liraglutide versus glimepiride monotherapy for type 2 diabetes (LEAD-3 Mono): a randomised, 52-week, phase III, double-blind, parallel-treatment trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.30.6.609

Liraglutide, a once-daily human GLP-1 analogue, added to a sulphonylurea over 26 weeks produces greater improvements in glycaemic and weight control compared with adding rosiglitazone or placebo in subjects with Type 2 diabetes (LEAD-1 SU)

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.30.6.609

Efficacy and safety comparison of liraglutide, glimepiride, and placebo, all in combination with metformin, in type 2 diabetes: the LEAD (liraglutide effect and action in diabetes)-2 study

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.30.6.609

Efficacy and safety of the human glucagon-like peptide-1 analog liraglutide in combination with metformin and thiazolidinedione in patients with type 2 diabetes (LEAD-4 Met+TZD).

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.30.6.609

Liraglutide vs insulin glargine and placebo in combination with metformin and sulfonylurea therapy in type 2 diabetes mellitus (LEAD-5 met+SU): a randomised controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.30.6.609

Liraglutide once a day versus exenatide twice a day for type 2 diabetes: a 26-week randomised, parallel-group, multinational, open-label trial (LEAD-6).

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.30.6.609

Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin as monotherapy in patients with type 2 diabetes mellitus.

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.30.6.609

Effect of the dipeptidyl peptidase-4 inhibitor sitagliptin as monotherapy on glycemic control in patients with type 2 diabetes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.30.6.609

Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin added to ongoing metformin therapy in patients with type 2 diabetes inadequately controlled with metformin alone.

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.30.6.609

Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin added to ongoing pioglitazone therapy in patients with type 2 diabetes: a 24-week, multicenter, randomized, double-blind, placebo-controlled, parallel-group study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.30.6.609

Effect of initial combination therapy with sitagliptin, a dipeptidyl peptidase-4 inhibitor, and metformin on glycemic control in patients with type 2 diabetes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.30.6.609

Glucose-lowering activity of the dipeptidyl peptidase-4 inhibitor saxagliptin in drug-naive patients with type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.30.6.609

The efficacy and safety of saxagliptin when added to metformin therapy in patients with inadequately controlled type 2 diabetes with metformin alone

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.30.6.609

Interim analysis of the effects of exenatide treatment on A1C, weight and cardiovascular risk factors over 82 weeks in 314 overweight patients with type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.30.6.609

Long-term effects of exenatide therapy over 82 weeks on glycaemic control and weight in over-weight metformin-treated patients with type 2 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.30.6.609

Mathematical modeling shows exenatide improved beta-cell function in patients with type 2 diabetes treated with metformin or metformin and a sulfonylurea

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.30.6.609

Increased risk of acute pancreatitis and biliary disease observed in patients with type 2 diabetes: a retrospective cohort study

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.30.6.609

Addition of biphasic, prandial, or basal insulin to oral therapy in type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.30.6.609

Effectiveness of progressive dose-escalation of exenatide (exendin-4) in reducing dose-limiting side effects in subjects with type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.30.6.609

Efficacy and safety of the dipeptidyl peptidase-4 inhibitor, sitagliptin, compared with the sulfonylurea, glipizide, in patients with type 2 diabetes inadequately controlled on metformin alone: a randomized, double-blind, non-inferiority trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.30.6.609

Efficacy and safety of incretin therapy in type 2 diabetes: systematic review and meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.30.6.609

Biology of incretins: GLP-1 and GIP

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.30.6.609

P2 Promoter Variants of the Hepatocyte Nuclear Factor 4 Gene Are Associated With Type 2 Diabetes in Mexican Americans

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.30.6.609

21 January 2018

Identifiers

DOI

10.1592/PHCO.30.6.609

1 reference

22 August 2017

1 reference

PubMed ID

20500049